OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 8.5 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).
Cancer Genetics and Epigenetics Alterations
Submission Deadline: October 31, 2020 (Open) Submit Now
Lunawati L Bennett, MS, PhD, PharmD, FACN
Professor of Pharmaceutical Sciences, Union University College of Pharmacy, Jackson, Tennessee
Research interests: role of antioxidants and nutraceuticals in cancer, pharmacogenomics, treatment of rare diseases, cancer genetics, leukemia, breast cancer, colorectal cancer, lung cancer, and brain cancer
About This Topic
Upcoming insight into understanding cancer genetics and epigenetic aberration of different type of cancers. Cancer is heterogeneous disease arise from defects in the structures of cells, aberration of genes, or alteration in key cellular pathways that regulate proliferation, differentiation, and apoptosis of normal cells. The mutations in cancer are usually due to gain-of-function of proto-oncogenes becomes oncogenes and/or loss function of tumor suppressor genes. Epigenetic mechanism also plays critical role in altering the patterns and levels of protein expression of certain genes, chromatin modifying protein, DNA methylation and patterns of gene expression in cancer cells. Although diverse mutations and gene expression changes have been implicated in cancer pathogenesis, the defects appear to limited number of gene alterations such as RAS, EGFR, PTEN, p53, Akt, PTEN and others; however, the accumulated multiple genetics and epigenetics defects play fundamental role in cancer initiation and progression.
This issue primary aims is to understand how persons genetics, chemical carcinogenesis, environment, gut microbes, dietary factors, and epigenetic alterations play important role in cancer initiation and progression.
Keywords: genetic defects; cancer alter signaling pathways; genomic integrity, oncogene mutations; tumor suppressor; proto oncogene; epigenetic alterations; chromatin regulator; histone hyper-methylation; histone hypo-methylation
Title: HDAC as potential therapeutic targets in glioblastoma therapy
Author: Luca Colucci-D’Amato
Title: Genetic variants of targetable cancer-related genes in vestibular schwannomas
Author: Cesar Wong
Abstract: A vestibular schwannoma (VS) is a benign primary intracranial tumor of the myelin-forming cells of the vestibulocochlear nerve (8th cranial nerve). A type of schwannoma, this tumor arises from the Schwann cells responsible for the myelin sheath that helps keep peripheral nerves insulated. The primary symptoms of vestibular schwannoma are unexplained progressive unilateral hearing loss and tinnitus and vestibular (disequilibrium) symptoms. Treatment of the condition is by surgery or radiation and often results in substantial or complete hearing loss in the affected ear. Observation (non-treatment) over time also usually results in hearing loss in the affected ear.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.